2025
Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes
Strober B, Bukhalo M, Armstrong A, Pariser D, Kircik L, Johnson B, Montgomery P, Dickerson T. Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes. Dermatology And Therapy 2025, 15: 1787-1796. PMID: 40349264, PMCID: PMC12126387, DOI: 10.1007/s13555-025-01441-y.Peer-Reviewed Original ResearchImprove patient outcomesPatient outcomesPrescribing behaviorStatistical analysis of concordanceTreatment-as-usual armPhysician prescribing behaviorWeek 4Clinical utilityBiologic drug classesDermal biomarker patchPhysician behaviorAnalysis of patientsManagement of patientsManagement of psoriasisUtilization findingsFisher's exact testHealthcare systemMedication changesInclusion of mindfulnessPhysiciansPsoriasis AreaPatient responseProspective studyLesional skinClinical endpointsA comparative analysis of lesional skin, sentinel flap, and mucosal biopsies in assessing acute face transplant rejection
Kauke-Navarro M, Huelsboemer L, Klimitz F, Diatta F, Knoedler L, Knoedler S, Crisler W, Brown S, Lian C, Repetto F, Clark R, Murphy G, Ko C, Pomahac B. A comparative analysis of lesional skin, sentinel flap, and mucosal biopsies in assessing acute face transplant rejection. Frontiers In Immunology 2025, 16: 1562024. PMID: 40236712, PMCID: PMC11997448, DOI: 10.3389/fimmu.2025.1562024.Peer-Reviewed Original ResearchConceptsNegative predictive valueSkin biopsiesFacial skin biopsiesMucosal biopsiesTransplant rejectionRejection eventsFlap biopsiesTransplant recipientsRejection gradeBanff classificationRejection activityLesional skinBiopsyMucosal tissuesSkin rejectionGrading systemPredictive valueFacial skinSentinel tissueMucosaRejection casesSentinelTransplantationSkinRejection patterns
2022
Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes
Strober B, Bukhalo M, Armstrong A, Pariser D, Kircik L, Parhami S, Montgomery P, Dickerson T. Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes. SKIN The Journal Of Cutaneous Medicine 2022, 6: 458-462. DOI: 10.25251/skin.6.6.2.Peer-Reviewed Original ResearchPhysician prescribing behaviorPatient outcomesPsoriasis patientsPrescribing behaviorClinical utilityExact testMatch StudyChoice of biologicsFisher's exact testPhysician decision makingBiologic selectionBiologic-naïveClinical outcomesLesional skinPsoriasis treatmentDrug classesPatient responsePatient managementWeek 4PatientsPhysician behaviorPhysiciansHealthcare systemBaselineInterim measurementsTopical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis
Mai Y, Ouyang Y, Yu M, Qin Y, Girardi M, Saltzman WM, Cocco E, Zhao C, Yu L, Jia Y, Xiao L, Dou L, Deng W, Liu Y, Xie J, Deng Y. Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis. Journal Of Controlled Release 2022, 349: 354-366. PMID: 35817278, DOI: 10.1016/j.jconrel.2022.07.006.Peer-Reviewed Original ResearchConceptsHealthy skinPsoriasis treatmentTopical formulationsPsoriatic skinCurrent psoriasis treatmentsFirst-line treatmentSingle-dose cureLocal drug concentrationModerate psoriasisLesional skinSingle doseDermal atrophyTherapeutic levelsTherapeutic efficacyCorticosteroidsDrug concentrationsPsoriasisBNPBasal cellsSkin retentionSkinLesionsBioadhesive nanoparticlesTreatmentStratum corneum
2019
Histopathologic findings characteristic of CARD14‐associated papulosquamous eruption
Ring NG, Craiglow BG, Panse G, Antaya RJ, Ashack K, Ashack R, Faith EF, Paller AS, McNiff JM, Choate KA, Ko CJ. Histopathologic findings characteristic of CARD14‐associated papulosquamous eruption. Journal Of Cutaneous Pathology 2019, 47: 425-430. PMID: 31849081, DOI: 10.1111/cup.13633.Peer-Reviewed Original ResearchConceptsPityriasis rubra pilarisPapulosquamous eruptionHistopathologic featuresPlaque psoriasisAdult patientsFollicular pluggingClinicopathologic findingsLesional skinRetrospective studyPatientsCARD14PilarisPathogenic mutationsDermal papillaPsoriasisRange of findingsHistopathologicAcanthosisAcantholysisOrthokeratosisParakeratosisFindingsSecond-Hit, Postzygotic PMVK and MVD Mutations in Linear Porokeratosis
Atzmony L, Khan HM, Lim YH, Paller AS, Levinsohn JL, Holland KE, Mirza FN, Yin E, Ko CJ, Leventhal JS, Choate KA. Second-Hit, Postzygotic PMVK and MVD Mutations in Linear Porokeratosis. JAMA Dermatology 2019, 155: 548-555. PMID: 30942823, PMCID: PMC6506890, DOI: 10.1001/jamadermatol.2019.0016.Peer-Reviewed Original ResearchConceptsLinear porokeratosisLesional skinWhole-exome sequencingAffected tissue samplesSomatic copy-neutral lossAcademic medical centerLines of BlaschkoSomatic mutationsT mutationNovel germline mutationPostzygotic somatic mutationsNovel somatic mutationsCoronoid lamellaBlood/saliva samplesGermline splice site mutationHistologic diagnosisHistologic examinationKeratotic papulesMedical CenterMAIN OUTCOMEAffected skinTherapeutic interventionsPorokeratosisWhorled configurationCopy-neutral loss
2018
Drug Repurposing Prediction for Immune-Mediated Cutaneous Diseases using a Word-Embedding–Based Machine Learning Approach
Patrick M, Raja K, Miller K, Sotzen J, Gudjonsson J, Elder J, Tsoi L. Drug Repurposing Prediction for Immune-Mediated Cutaneous Diseases using a Word-Embedding–Based Machine Learning Approach. Journal Of Investigative Dermatology 2018, 139: 683-691. PMID: 30342048, PMCID: PMC6387843, DOI: 10.1016/j.jid.2018.09.018.Peer-Reviewed Original ResearchConceptsImmune-mediated diseasesCutaneous diseaseEfficient bioinformatics approachBioinformatics approachDrug-disease relationshipsDrug repurposing approachChronic inflammatory condition of skinChronic inflammatory conditionsSequencing cohortPsoriatic lesional skinReceiver Operating CharacteristicRNA-sequencing cohortsClinical efficacyTreat other diseasesLesional skinAutoimmune diseasesRepurposing approachDrug repurposingCondition of skinOther diseasesDrugDiseaseSkin Microbiota as Antigenic Triggers for Cutaneous T Cell Lymphoma
Dehner C, Ruff W, Foss F, Girardi M, Kriegel M. Skin Microbiota as Antigenic Triggers for Cutaneous T Cell Lymphoma. The Journal Of Immunology 2018, 200: 166.24-166.24. DOI: 10.4049/jimmunol.200.supp.166.24.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaT cellsSkin lesionsCell lymphomaPathogenesis of CTCLActive skin lesionsCutaneous T-cellChronic skin lesionsAdaptive immune responsesPatient T cellsSLE patientsCTCL patientsAntigenic triggerLesional skinRRNA sequencingAntigenic challengeMALT lymphomaHealthy donorsImmune responseAntigenic driversSkin commensalsPatient biopsiesClonal proliferationV1-3
2013
TRPA1-Dependent Pruritus in IL-13–Induced Chronic Atopic Dermatitis
Oh MH, Oh SY, Lu J, Lou H, Myers AC, Zhu Z, Zheng T. TRPA1-Dependent Pruritus in IL-13–Induced Chronic Atopic Dermatitis. The Journal Of Immunology 2013, 191: 5371-5382. PMID: 24140646, PMCID: PMC4175413, DOI: 10.4049/jimmunol.1300300.Peer-Reviewed Original ResearchMeSH KeywordsAcetanilidesAnimalsCalcium ChannelsCells, CulturedChronic DiseaseCytokinesDermatitis, AtopicDisease Models, AnimalHumansInterleukin-13Mast CellsMiceMice, Inbred C57BLMice, TransgenicNerve FibersNerve Tissue ProteinsNeuropeptidesPruritusPurinesTh1-Th2 BalanceTransient Receptor Potential ChannelsTRPA1 Cation ChannelUp-RegulationConceptsTransient receptor potential ankyrin 1Chronic atopic dermatitisAtopic dermatitisMast cellsChronic itchTRPA1 expressionAfferent nervesIL-13Nerve fibersInhibition of TRPA1Histamine-independent itchSensory nerve fibersAfferent nerve fibersDorsal root gangliaNovel neural mechanismAD skinAD miceItch pathwaysLesional skinRoot gangliaInflammatory environmentHealthy subjectsSpecific antagonistMouse modelAnkyrin 1
2012
Epicutaneous Exposure to Staphylococcal Superantigen Enterotoxin B Enhances Allergic Lung Inflammation via an IL-17A Dependent Mechanism
Yu J, Oh MH, Park JU, Myers AC, Dong C, Zhu Z, Zheng T. Epicutaneous Exposure to Staphylococcal Superantigen Enterotoxin B Enhances Allergic Lung Inflammation via an IL-17A Dependent Mechanism. PLOS ONE 2012, 7: e39032. PMID: 22848348, PMCID: PMC3407176, DOI: 10.1371/journal.pone.0039032.Peer-Reviewed Original ResearchConceptsIL-17A-dependent mechanismsAtopic dermatitisAirway hyperresponsivenessAtopic marchLung inflammationDependent mechanismDevelopment of ADSeverity of ADEnterotoxin BSystemic Th2 responseAllergic lung inflammationTh17/ILSkin barrier abnormalitiesIL-6 productionSkin of patientsEpicutaneous exposureAllergic rhinitisIL-17ATh2 responsesEpicutaneous sensitizationLymph nodesImmune environmentLesional skinAllergen ovalbuminStimulating lymphocytes
2011
Post‐epidemic eosinophilia–myalgia syndrome associated with L‐tryptophan
Allen JA, Peterson A, Sufit R, Hinchcliff ME, Mahoney JM, Wood TA, Miller FW, Whitfield ML, Varga J. Post‐epidemic eosinophilia–myalgia syndrome associated with L‐tryptophan. Arthritis & Rheumatism 2011, 63: 3633-3639. PMID: 21702023, PMCID: PMC3848710, DOI: 10.1002/art.30514.Peer-Reviewed Original ResearchConceptsEosinophilia-myalgia syndromeL-tryptophan-associated eosinophilia-myalgia syndromeNew casesL-tryptophanGrowth factor βChronic neuropathyPeripheral eosinophiliaSubacute onsetLesional skinSkin indurationImmunogenetic featuresInterleukin-4Drug AdministrationFDA banFactor βSyndromeMyalgiaEosinophiliaNeuropathyHistopathologicIndurationIncidenceAdministration
2009
A non-Smad mechanism of fibroblast activation by transforming growth factor-β via c-Abl and Egr-1: selective modulation by imatinib mesylate
Bhattacharyya S, Ishida W, Wu M, Wilkes M, Mori Y, Hinchcliff M, Leof E, Varga J. A non-Smad mechanism of fibroblast activation by transforming growth factor-β via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 2009, 28: 1285-1297. PMID: 19151753, PMCID: PMC4006376, DOI: 10.1038/onc.2008.479.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzamidesBleomycinCells, CulturedCollagenEarly Growth Response Protein 1Extracellular Signal-Regulated MAP KinasesFibroblastsFibrosisHumansImatinib MesylateMiceMice, Inbred BALB CNIH 3T3 CellsPiperazinesProtein Kinase InhibitorsProto-Oncogene Proteins c-ablPyrimidinesSignal TransductionSmad2 ProteinSmad3 ProteinTransforming Growth Factor betaConceptsChronic myelogenous leukemiaFibrotic responseEgr-1Growth factorUpregulated tissue expressionFibrosis of skinNovel therapeutic approachesEarly growth response factor-1Kinase-deficient mutant formC-AblNormal fibroblastsTGF-β stimulationIntracellular signaling mechanismLesional skinStimulation of collagenImatinib mesylateMouse embryonic fibroblastsFibrotic processMyelogenous leukemiaTherapeutic approachesPharmacological targetingTarget of inhibitionTGF-β responseFibroblast activationC-Abl activation
1994
Inducibility and Expression of Microvascular Endothelial Adhesion Molecules in Lesional, Perilesional, and Uninvolved Skin of Psoriatic Patients
Petzelbauer P, Pober J, Keh A, Braverman I. Inducibility and Expression of Microvascular Endothelial Adhesion Molecules in Lesional, Perilesional, and Uninvolved Skin of Psoriatic Patients. Journal Of Investigative Dermatology 1994, 103: 300-305. PMID: 7521374, DOI: 10.1111/1523-1747.ep12394720.Peer-Reviewed Original ResearchConceptsVascular cell adhesion molecule-1Endothelial leukocyte adhesion molecule-1Lesional skinAdhesion molecule-1Psoriatic patientsEndothelial cellsUninvolved skinPerilesional skinMolecule-1Dermal microvasculatureCapillary loopsCell adhesion molecule-1Perivascular inflammatory infiltratesLeukocyte adhesion molecule-1VCAM-1 expressionTumor necrosis factorEndothelial adhesion moleculesMicrovascular endothelial cellsEndothelial cell expressionVenular endothelial cellsInflammatory infiltrateEpidermal involvementPsoriatic plaquesSuperficial plexusNecrosis factor
1990
Unilateral Cutaneous Emboli of Aspergillus
Watsky K, Eisen R, Bolognia J. Unilateral Cutaneous Emboli of Aspergillus. JAMA Dermatology 1990, 126: 1214-1217. PMID: 2396839, DOI: 10.1001/archderm.1990.01670330094015.Peer-Reviewed Case Reports and Technical NotesConceptsLeft upper extremityLeft subclavian arteryBone marrow transplantationAcute nonlymphocytic leukemiaSkin biopsy specimenBroad-spectrum antibioticsCutaneous emboliHyphae consistentPulmonary aspergillomaSubclavian arteryMarrow transplantationPurpuric maculesLesional skinChemotherapeutic regimensNonlymphocytic leukemiaBiopsy specimenUpper extremityFrozen sectionsDay 53White womenLeft handNecrotic centerEmboliFeverMagnetic resonance
1987
Electron microscopic and immunolabeling studies of the lesional and normal skin of patients with mycosis fungoides treated by total body electron beam irradiation
Braverman I, Klein S, Grant A. Electron microscopic and immunolabeling studies of the lesional and normal skin of patients with mycosis fungoides treated by total body electron beam irradiation. Journal Of The American Academy Of Dermatology 1987, 16: 61-74. PMID: 3100584, DOI: 10.1016/s0190-9622(87)70005-x.Peer-Reviewed Original ResearchConceptsEpidermal Langerhans cellsElectron beam therapyLangerhans cellsMycosis fungoidesIndeterminate cellsNormal skinDisease courseLesional skinBeam therapySkin lesionsNonspecific skin lesionsPatient's disease courseIa-positive cellsEpidermal cell suspensionsEpidermal thymocyteClinical remissionBiopsy specimensPretreatment levelsIa antigensFungoidesTherapyLesionsSkinPatientsCells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply